LR-HEALTH-&-BEAUTY
18.6.2020 17:49:09 CEST | Business Wire | Press release
Today, the LR LIFETAKT NIGHT MASTER product was awarded the German Brand Award 2020. This is a sensational success for the LR Health & Beauty company, which launched a new segment in its health portfolio with this sleep drink.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200618005674/en/
In the “Excellent Brands” competition, the vegan, holistically designed product impressed the jury in the “Health & Pharmaceuticals” category as one of the best product brands in the industry. The nightcap also received a “Special Mention” in the cross-industry category “Product Brand of the Year”, in which the jury awards a prize for special aspects of brand management. The German Brand Institute already distinguished LR as a winner in 2019 in the “Beauty & Care” category for its 5in1 Beauty Elixir product.
“The second award in a row for an advanced product development makes me and makes us all, incredibly proud and happy, and highlights our expertise in the health field,” says Andreas Friesch, CEO of LR Health & Beauty. “True to the company motto ‘More quality for your life’, we have developed a natural, effective, non-addictive product that is in touch with today’s trends*. Receiving recognition for this motivates us to keep developing innovative product solutions in the future,” Friesch says.
The secret of healthy sleep: LR LIFETAKT NIGHT MASTER
Healthy sleep improves quality of life, strengthens the immune system and heightens performance. Sleep is a desperate challenge for many but it does not have to be.*
The NIGHT MASTER sleep drink from LR LIFETAKT is an effective dietary supplement that ensures a restful sleep over the long term, in a healthy way that is non-addictive. Natural and scientifically proven active ingredients like hops and saffron extract, aloe vera, the amino acid L-tryptophan, magnesium and zinc, as well as a vitamin B complex distinguish the highly bioavailable formula. With its threefold effect, the product promotes relaxation when falling asleep and relaxation while sleeping through the night, as well as optimized regeneration. The product is vegan and it is gluten, lactose and sugar free. www.LRNightMaster.com
German Brand Award | German Design Council
The German Brand Award is a competition presented by the German Brand Institute. The Institute was founded by the German Design Council (Rat für Formgebung) in order to strengthen brand management as a crucial factor for success in companies in the national and international competitive field. It is a driving force of German brand economy, bringing together major brand-builders and stimulating brand dialog. The German Brand Award presented by the Institute is one of the most notable German brand awards.
The German Design Council is an independent and internationally active institution that supports companies in efficiently communicating design and brand competence, while at the same time aiming to strengthen design awareness among the general public. More information at: german-brand-award.com
LR Health & Beauty
Under the motto “More quality for your life”, the LR Group of Companies, with headquarters in the German city of Ahlen, markets diverse beauty and health products in 28 different countries. These include skin care and color cosmetics, dietary supplements and fragrances. LR Health & Beauty has made it its goal to improve the well-being and health of people through its product portfolio. That is why the company keeps developing new products – from the forces of nature combined with the latest scientific discoveries. Aloe Vera has been one of LR's key competences for over 18 years, where we only use the precious leaf fillet is used. With approximately 1,200 employees and thousands of registered sales partners and customers, LR is one of the leading direct sales companies in Europe. The company has been assisting children in need and their families in various countries around the world through the LR Global Kids Fund e.V. – in a fast and non-bureaucratic way in cooperation with local established institutions.
*78% of Germans suffer from sleep problems, according to a nationwide CATI-representative survey conducted by Mente>factum on behalf of LR in 2019
View source version on businesswire.com: https://www.businesswire.com/news/home/20200618005674/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom